Role of allogeneic stem cell transplantation in multiple myeloma

Expert Review of Anticancer Therapy

Volumn 5, Issue 3, 2005, Pages 455-464

  Thomson, Kirsty J ^a   Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic hemopoietic stem cell transplantation; Autologous hemopoietic stem cell transplantation; Donor lymphocyte infusion; Graft versus host disease; Graft versus myeloma; Myeloma

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGEN; IMMUNOGLOBULIN IDIOTYPE; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DONOR; DRUG MEGADOSE; ERADICATION THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; LONGEVITY; LYMPHOCYTE TRANSFUSION; META ANALYSIS; MORBIDITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRAFT VS TUMOR EFFECT; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 21244452378     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.3.455     Document Type: Review

References (64)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91(1), 3-21 (1998).
2. Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl. J. Med. 351(18), 1860-1873 (2004).
3. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2(8354), 822-824 (1983).
4. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70(3), 869-872 (1987).
5. Jagannath S, Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematol. Oncol. Clin. North Am. 6(2), 437-449 (1992).
6. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 84(3), 950-956 (1994).
7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335(2), 91-97 (1996).
8. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348(19), 1875-1883 (2003).
9. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br. J. Haematol. 114(3), 600-607 (2001).
10. Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104(10), 3052-3057 (2004).
11. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma. patients with renal failure. Br. J. Haematol. 114(4), 822-829 (2001).
12. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 30(10), 673-679 (2002).
13. Vesole DH, Crowley JJ, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J. Clin. Oncol. 17(7), 2173-2179 (1999).
14. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99(3), 731-735 (2002).
15. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J. Clin. Oncol. 1907), 3771-3779 (2001).
16. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9), 3131-3136 (1998).
17. Cavo M, Cellini C, Zimagni E et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood 104(11), 536a (2004).
18. Fermand JP. Alberti C, Marolleau JP. Single versus double high dose therapy supported with autologous blood stem cell transplantation using selected or unselected CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with myeloma. Hematol. J. 4(Suppl. 1), S59 (2003).
19. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349(26), 2495-2502 (2003).
20. Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant 35(3), 215-224 (2005).
21. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
22. Barlogie B, Zangari M, Spencer T et al. Thalidomide in the management of multiple myeloma. Semin. Hematol. 38(3), 250-259 (2001).
23. Richardson PG, Jagannath R, Schlossman R et al. A multi-center, randomized Phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 102(11), 825a (2003).
24. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
25. Gahrton G, Svensson H, Bjorkstrand B et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 24(7), 741-745 (1999).
26. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12), 2462-2465 (1990).
27. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 87(3), 1196-1198 (1996).
28. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N. Engl J. Med. 325(18), 1267-1273 (1991).
29. Cavo M, Benni M, Cirio TM, Gozzetti A, Tura S. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. Stem Cells 13(Suppl. 2), 126-131 (1995).
30. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88(7), 2787-2793 (1996).
31. Ballen K, King R, Carston M et al. Outcome of unrelated transplants in patients with multiple myeloma. Blood 96(Suppl. 1), 414a (2000).
32. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88(12), 4711-4718 (1996).
33. Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 96(1), 355-357 (2000).
34. Corradini P, Cavo M, Lokhorst H et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102(5), 1927-1929 (2003).
35. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 17(1), 208-215 (1999).
36. Lokhorst HM, Segeren CM, Verdonck LF et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the Phase III study HOVON 24 MM. J. Clin. Oncol. 21(9), 1728-1733 (2003).
37. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Clin. Oncol. 13(6), 1312-1322 (1995).
38. Hunter HM, Peggs K, Powles R et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation. Br. J. Haematol. 128(4), 496-502 (2005).
39. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br. J. Haematol. 113(1), 209-216 (2001).
40. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86(5), 2041-2050 (1995).
41. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90(10), 4206-4211 (1997).
42. Peggs KS, Mackinnon S, Williams CD et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol. Blood Marrow Transplant 9(4), 257-265 (2003).
43. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86(4), 1261-1268 (1995).
44. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990).
45. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76(2), 418-423 (1990).
46. + cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 57(1), 82-87 (1994).
47. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91(10), 3671-3680 (1998).
48. + T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 63(10), 2561-2568 (2003).
49. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002).
50. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 93(7), 2411-2419 (1999).
51. Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101 (11), 4607-4610 (2003).
52. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94(2), 673-683 (1999).
53. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 108(4), 805-816 (2000).
54. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345(8956), 1016-1020 (1995).
55. Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood (2005) (In Press).
56. Einsele H, Schafer HJ, Hebart H et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br. J. Haematol. 121(3), 411-418 (2003).
57. Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning folowing cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102(9), 3447-3454 (2003).
58. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100(3), 755-760 (2002).
59. Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome-13 abnormalities identified by FISH analysis and serum β-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97(6), 1566-1571 (2001).
60. Moreau P, Garban F, Facon T et al. Preliminary results of the IFM9903 and IFM9904 protocols comparing autologous followed by miniallogeneic transplantation and double autologous transplant in high-risk de novo multiple myeloma. Blood 102(11), 138a (2003).
61. Kroger N, Schilling G, Einsele H et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103(11), 4056-4061 (2004).
62. Bruno B, Patriarca F, Rotta M et al. Autografting followed by low dose TBI based non-myeloablative allografting in newly diagnosed multiple myeloma: the Italian experience. Blood 102(11), 693a (2003).
63. Kroger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100(12), 3919-3924 (2002).
64. Shaw BE, Peggs K, Bird JM et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br. J. Haematol. 123(5), 886-895 (2003).